Characteristics |  | Low basophils (n = 40) |  | High basophils (n = 23) |  | p value |
---|---|---|---|---|---|---|
Age, mean (SD) | Â | 52.0 (14.0) | Â | 54.3 (10.0) | Â | 0.366 |
Gender | Male | 20 | 50.0% | 16 | 69.6% | 0.131 |
 | Female | 20 | 50.0% | 9 | 30.4% |  |
ECOG PS | 0 | 27 | 67.5% | 17 | 73.9% | 0.593 |
 | 1 ~ 2 | 13 | 32.5% | 6 | 26.1% |  |
BMI, mean (SD) | Â | 21.3 (2.91) | Â | 21.1 (3.05) | Â | 0.687 |
Tumor location | GEJ | 9 | 22.5% | 6 | 26.1% | 0.748 |
 | Stomach | 31 | 77.5% | 17 | 73.9% |  |
Tumor differentiation | Well-moderate | 4 | 10.0% | 2 | 8.7% | 0.968 |
 | Poor | 32 | 80.0% | 19 | 82.6% |  |
 | Unknown | 4 | 10.0% | 2 | 8.7% |  |
Lines of anti-PD-1 therapy | First line | 24 | 60.0% | 12 | 52.2% | 0.546 |
 | Second line or later | 16 | 40.0% | 11 | 47.8% |  |
Cycles of anti-PD-1 therapy, median (IQR) |  | 5 (4–8) |  | 5 (4–7) |  | 0.549 |
HER2 status | Positive | 5 | 12.5% | 2 | 8.7% | 0.644 |
 | Negative | 35 | 87.5% | 21 | 91.3% |  |
PD-L1 expression | CPS ≥ 1 | 33 | 82.5% | 17 | 73.9% | 0.417 |
 | CPS < 1 | 7 | 17.5% | 6 | 26.1% |  |
MMR status | pMMR | 36 | 90.0% | 17 | 73.9% | 0.042 |
 | dMMR | 3 | 7.5% | 1 | 4.3% |  |
 | Unknown | 1 | 2.5% | 5 | 21.7% |  |
EBV status | Positive | 2 | 5.0% | 2 | 8.7% | 0.199 |
 | Negative | 35 | 87.5% | 16 | 69.6% |  |
 | Unknown | 3 | 7.5% | 5 | 21.7% |  |
Number of organs with metastasis, median (IQR) |  | 2.0 (1–2) |  | 2 (1–2) |  | 0.637 |
NLR, mean (SD) | Â | 3.80 (3.15) | Â | 2.77 (1.68) | Â | 0.357 |
LMR, mean (SD) | Â | 2.91 (4.90) | Â | 3.21 (1.16) | Â | 0.539 |